Literature DB >> 22120672

Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets.

Caroline Gest1, Pezhman Mirshahi, Hong Li, Linda-Louise Pritchard, Ulrich Joimel, Emmanuel Blot, Jean Chidiac, Bernard Poletto, Jean-Pierre Vannier, Remi Varin, Massoud Mirshahi, Lionel Cazin, Eric Pujade-Lauraine, Jeannette Soria, Claudine Soria.   

Abstract

Seeking to improve ovarian cancer therapy, we compared biological characteristics of the moderately-aggressive OVCAR-3 cell line with two highly aggressive ovarian cancer cell populations: the SK-OV-3 cell line, and HASCJ primary cells isolated from the ascitic fluid of a patient with FIGO stage IV ovarian cancer. Secretion of angiogenic factors was not discriminative, whereas cell invasion through Matrigel and vasculogenic mimicry were much greater in the more aggressive cells. Among 10 agents tested for their ability to decrease cancer cell aggressivity using these two models, inhibitors of Stat3, IGF-IR and Rho GTPase were found to be the most promising.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22120672     DOI： 10.1016/j.canlet.2011.11.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  15 in total

1.  A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Authors:  Marc A Becker; Paul Haluska; Laurie K Bale; Claus Oxvig; Cheryl A Conover
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

2.  miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R.

Authors:  Na Li; Xiaosu Zhao; Lufei Wang; Shi Zhang; Manhua Cui; Jin He
Journal:  Tumour Biol       Date:  2015-12-22

3.  Atypical protein kinase C zeta: potential player in cell survival and cell migration of ovarian cancer.

Authors:  Kelly K Y Seto; Irene L Andrulis
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

4.  Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.

Authors:  Nana Jin; Hao Wu; Zhengqiang Miao; Yan Huang; Yongfei Hu; Xiaoman Bi; Deng Wu; Kun Qian; Liqiang Wang; Changliang Wang; Hongwei Wang; Kongning Li; Xia Li; Dong Wang
Journal:  Sci Rep       Date:  2015-06-23       Impact factor: 4.379

5.  Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2/STAT3 signaling pathway in an ovarian cancer cell line.

Authors:  Nadia Benabbou; Pezhman Mirshahi; Mélodie Cadillon; Jeannette Soria; Amu Therwath; Massoud Mirshahi
Journal:  Int J Oncol       Date:  2013-07-15       Impact factor: 5.650

6.  Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.

Authors:  Lifeng Yang; Tyler Moss; Lingegowda S Mangala; Juan Marini; Hongyun Zhao; Stephen Wahlig; Guillermo Armaiz-Pena; Dahai Jiang; Abhinav Achreja; Julia Win; Rajesha Roopaimoole; Cristian Rodriguez-Aguayo; Imelda Mercado-Uribe; Gabriel Lopez-Berestein; Jinsong Liu; Takashi Tsukamoto; Anil K Sood; Prahlad T Ram; Deepak Nagrath
Journal:  Mol Syst Biol       Date:  2014-05-05       Impact factor: 11.429

7.  MicroRNA-519a inhibits the proliferation and promotes the apoptosis of ovarian cancer cells through targeting signal transducer and activator of transcription 3.

Authors:  Fei Tian; Ligang Jia; Zhaoping Chu; Hua Han; Yuan Zhang; Jianhui Cai
Journal:  Exp Ther Med       Date:  2017-12-06       Impact factor: 2.447

8.  Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma.

Authors:  J Glaser; M H D Neumann; Qi Mei; B Betz; N Seier; I Beyer; T Fehm; H Neubauer; D Niederacher; M C Fleisch
Journal:  Biomed Res Int       Date:  2014-04-02       Impact factor: 3.411

9.  Improvement of human keratinocyte migration by a redox active bioelectric dressing.

Authors:  Jaideep Banerjee; Piya Das Ghatak; Sashwati Roy; Savita Khanna; Emily K Sequin; Karen Bellman; Bryan C Dickinson; Prerna Suri; Vish V Subramaniam; Christopher J Chang; Chandan K Sen
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

10.  Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.

Authors:  W J Sheng; H Jiang; D L Wu; J H Zheng
Journal:  Braz J Med Biol Res       Date:  2013-08-13       Impact factor: 2.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.